Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
An analysis of data from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial showed that the older a woman is at diagnosis of hormone-sensitive breast cancer, the greater her chance of distant recurrence over time. Distant recurrence refers to cancer that has spread to a part of the body beyond the breast and regional lymph nodes.
The National Comprehensive Cancer Network (NCCN) issued new guidelines that help doctors focus on the post-treatment needs of individuals diagnosed with and treated for cancer.
Research presented at the 2013 Annual Meeting of the American Association for Cancer Research found that African-American women have worse breast cancer-specific survival rates than women of other racial or ethnic groups, no matter the tumor subtype.
Overweight and obese women who had surgery plus radiation therapy to treat breast cancer, and who had 12 or more lymph nodes removed, were more likely to develop lymphedema than women of normal weight, an analysis showed.
A study of about 7,000 women treated with tamoxifen for early-stage, ER+ breast cancer showed lower recurrence and mortality rates for those who took the medication for 10 years instead of 5 years. This research, which has not yet been published, reinforces the findings of the international ATLAS trial.
In a recent study, researchers found that most women diagnosed with breast cancer do not meet national physical activity guidelines in the 10 years after diagnosis.
New findings show women treated for breast cancer who report trouble with memory and problem solving skills do perform worse on tests of cognitive function than women who were never diagnosed. Cognitive function refers to a person’s attention, memory, and ability to reason, learn and understand.
New research shows triple-negative breast cancer tumors may have high levels of a certain protein in common. Identification of this protein may lead to better understanding of how the cancer grows, and how to more effectively treat it in the future.
Through a subanalysis of data from EMILIA, the clinical trial that led to FDA approval of T-DM1, researchers found that the amount of HER2 messenger RNA (mRNA) present in HER2 positive, metastatic tumors may predict how well that breast cancer will respond to the medicine. Messenger RNA is a type of molecule that carries genetic information to help make proteins. The more mRNA measured on tumor cells, the more HER2 proteins present, and the more responsive those cells will be to T-DM1.
Young women whose surgery-only breast cancer treatment is delayed longer than 6 weeks have decreased survival rates compared with women who are treated sooner.